Cargando…
Pharmacokinetics, Safety, and Tolerability of GLPG0259, a Mitogen-Activated Protein Kinase-Activated Protein Kinase 5 (MAPKAPK5) Inhibitor, Given as Single and Multiple Doses to Healthy Male Subjects
BACKGROUND AND OBJECTIVES: GLPG0259 is a small-molecule inhibitor of mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5), a kinase enzyme that plays a role in important inflammatory pathways. The main objectives of the phase I clinical studies in early development were to characte...
Autores principales: | Namour, Florence, Vanhoutte, Frédéric P., Beetens, Johan, Blockhuys, Stan, Weer, Marc De, Wigerinck, Piet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585965/ https://www.ncbi.nlm.nih.gov/pubmed/22950522 http://dx.doi.org/10.2165/11633120-000000000-00000 |
Ejemplares similares
-
The Role of Mitogen-Activated Protein Kinase-Activated Protein Kinases (MAPKAPKs) in Inflammation
por: Moens, Ugo, et al.
Publicado: (2013) -
Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects
por: Namour, Florence, et al.
Publicado: (2016) -
Is Mitogen‐Activated Protein Kinase Phosphatase 5 a Solution to the Puzzle of the Mitogen‐Activated Protein Kinase Signal in Steatohepatitis?
por: Miura, Kouichi, et al.
Publicado: (2019) -
Homology modeling and ligand docking of Mitogen-activated protein kinase-activated protein kinase 5 (MK5)
por: Lindin, Inger, et al.
Publicado: (2013) -
Comparative Molecular Dynamics Simulations of Mitogen-Activated Protein Kinase-Activated Protein Kinase 5
por: Lindin, Inger, et al.
Publicado: (2014)